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Abstract
Objective To evaluate the accumulated information from genetic
association studies investigating the impact of variants of the cytochrome
P450 (CYP) 2C19 genotype on the clinical efficacy of clopidogrel.
Design Systematic review and meta-analysis with a structured search
algorithm and prespecified eligibility criteria for retrieval of relevant
studies; dominant genetic model assumptions and quantitative methods
for calculating summary effect estimates from study level odds ratios;
systematic assessment of bias within and between studies; and grading
of the cumulative evidence by consensus criteria.
Data sources Medline, Embase, the Cochrane Library, online databases,
contents pages and bibliographies of general medical, cardiovascular,
pharmacological, and genetic journals.
Eligibility criteria for selecting studies Original full length reports
assessing the cumulative incidence of major adverse cardiovascular
events or stent thrombosis over a follow-up period of at least a month
in association with carrier status for the loss of function or gain of function
CYP2C19 allele in adult patients with coronary artery disease and a
clinical presentation of acute coronary syndrome or stable angina pectoris
who were taking clopidogrel.
Results 15 studies met the inclusion criteria. The random effects
summary odds ratio for stent thrombosis in carriers of at least one
CYP2C19 loss of function allele versus non-carriers combining nine
studies was 1.77 (95% confidence interval 1.31 to 2.40; P<0.001). This
nominally significant odds ratio was subject to considerable bias across
the studies (small study effect bias and replication diversity). The
adjustment for these quality modifiers tended to abolish the association.
The corresponding random effects summary odds ratio of major adverse
cardiovascular events for 12 studies combined was 1.11 (0.89 to 1.39;
P=0.36). The random effects summary odds ratio of stent thrombosis in
carriers versus non-carriers of at least one CYP2C19*17 gain of function
allele for three studies combined was 0.99 (0.60 to 1.62; P=0.96), and
the corresponding odds ratio of major adverse cardiovascular events in
five studies was 0.93 (0.75 to 1.14; P=0.48). The overall quality of
epidemiological evidence was graded as low, which excludes reliable
clinical assessments.
Conclusions Accumulated information from genetic association studies
does not indicate a substantial or consistent influence of CYP2C19 gene
polymorphisms on the clinical efficacy of clopidogrel. The current
evidence does not support the use of individualised antiplatelet regimens
guided by CYP2C19 genotype.
Introduction
Along with aspirin, clopidogrel represents the mainstay of
antiplatelet treatment for preventing thromboembolic events in
patientswithischaemiccardiovasculardiseases.
1Itisthesecond
biggest selling drug, with global sales of more than $9bn
(£5.6bn, €6.3bn) a year.
2 A major drawback to its use is its
unpredictable clinical efficacy, with insufficient platelet
inhibition in about 20% of patients,
3 resulting in a higher
incidence of atherothrombotic events.
4-6
The primary source of variability in responsiveness to
clopidogrel might lie in its pharmacokinetics. Clopidogrel is a
prodrug that is transformed into its active metabolite through
metabolic pathways involving cytochrome (CYP) P450
isoenzymes. CYP2C19 might be the crucial isoenzyme for the
metabolic bioactivation of clopidogrel.
7 Accordingly,
polymorphisms of the CYP2C19 gene associated with loss of
function have been associated with decreased antiplatelet
responsiveness
8 and are supposed to predict a large proportion
of the variability in clinical response to clopidogrel.
9 The
quantitative relations between the presence of loss of function
variants (specifically the most common *2 variant) and the risk
of ischaemic cardiovascular events associated with use of
clopidogrel have been summarised in five systematic reviews
abstracting data from genetic association studies published up
to2009.
10-14Thereportedsummaryeffectestimatesconsistently
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Research
RESEARCHshowed that carriers of a loss of function allele had about 1.5
to two times the risk of occurrence of a major adverse
cardiovascular event or cardiovascular death compared with
non-carriers. Particularly strong associations were found with
the risk of stent thrombosis in patients who had undergone
percutaneous coronary intervention. Patients who had at least
one reduced function allele of CYP2C19 were about three or
four times more likely to experience a stent thrombosis than
non-carriers.
10-14 Based on this evidence, CYP2C19 seems to be
a major determinant of efficacy of clopidogrel. Therefore,
determining a patient’s CYP2C19 genotype could be a
straightforward diagnostic approach for optimising antiplatelet
treatment and improving clinical outcome.
9
In March 2010 the US Food and Drug Administration (FDA)
issued a boxed warning on the clopidogrel label emphasising
that individuals with a reduced function CYP2C19 genotype
areatanincreasedriskofadversecardiovascularoutcomesand
advocating strategies for adjustment of clopidogrel dose or the
use of alternative antiplatelet agents in these high risk
individuals.
15 In accomplishing the strategy of genotype guided
clopidogrel treatment, the FDA subsequently approved a
validated genotyping assay for detecting variant genes of
CYP2C19 (AutoGenomics CYP2C19 Assay, 510(k) clearance
received October 2010).
Complementary to the associations between reduced function
CYP2C19allelesandincreasedcardiovascularrisk,thecommon
CYP2C19*17 gain of function allele has been associated with
a better antiplatelet response to clopidogrel.
16 17 Several studies
have examined the possible linkage of CYP2C19*17 with
clinicalefficacyoutcomes.Resultsmightbeexpectedtomirror
the interaction with loss of function alleles, with lower risks of
events in carriers of the *17 allele than in non-carriers.
Large genetic association studies published in 2010, however,
failedtoreplicatethestrongassociationsofthereducedfunction
alleles with cardiovascular outcomes.
18 19 Moreover, the results
of a detailed biochemical investigation question a direct
mechanistic involvement of CYP2C19 in the bioactivation of
clopidogrel.
20
We examined whether the new findings affect the strength of
theassociationbetweenCYP2C19genotypeandclinicalefficacy
of clopidogrel and whether the appraisal of the interaction
between CYP2C19 and clopidogrel needs revision. We carried
out a systematic review and meta-analysis of the accumulated
information of association studies between loss of function or
gain of function gene variants with clinical efficacy outcomes.
Wesystematicallyassessedthequalityoftheindividualstudies
and the risk of biases between the studies according to general
epidemiologicalandspecificgeneticitems.Weusedconsensus
criteria for rating the overall evidence of the meta-analyses to
quantify the confidence of the effect estimates for guiding
clinical decisions.
Methods
Our meta-analysis adhered to the MOOSE and PRISMA
statementsforreportingonsystematicreviewsandtheSTREGA
recommendations for reporting of genetic association studies.
Weconductedthemeta-analysisinaccordancewiththegeneral
guidelines of the Cochrane Handbook for Systematic Reviews
of Interventions, version 5.0.2, and the specific
recommendationsofgeneticmeta-analysisoftheHuGEReview
Handbook, version 1.0.
Information sources and search strategy
We searched Medline (from 1966 to 31 December 2010),
Embase (from 1974 to 31 December 2010), and the Cochrane
Library (from 1980 to 31 December 2010) without language
restrictions. The search algorithm combined the categories for
“drug”,“gene”,and“outcome”bytheBooleanoperator“AND”.
The search terms (medical subject headings and text words) in
each category were combined with the operator “OR”. The
algorithmwastrimmedformaximumsensitivitybysequentially
adding search items in each category until the total number of
hits did not increase further. At each step we determined the
explanatory power of the algorithm by testing that the removal
of any item resulted in a lower number of total hits. We
determined the specificity of the algorithm by testing that the
combination of the three search categories yielded fewer hits
than any combination of two categories. The following search
strategy was applied: (clopidogrel OR plavix OR iscover OR
thienop* OR P2Y12) AND (associat* OR cytochrome OR cyp
ORpolymorph*ORgenetic*ORmetabolis*ORenzyme)AND
(cardiov* OR vascular OR coronar* OR stent* OR thrombos*
OR myocar* OR heart OR infarct* OR death OR stroke OR
ischem*).
Inaddition,wesearchedtheonlinedatabasesofgeneralmedical,
cardiovascular,pharmacological,andgeneticjournalsasindexed
by ISI Web of Science to identify advance online publications.
We hand searched the contents pages of the 2005-10 issues of
these journals and the bibliographies of relevant articles to
retrieve further potential publications.
We fixed 31 December 2010 as the cut-off date for inclusion
of new studies, avoiding subjectivities in the choice of the time
point when new information is reviewed and allowing calendar
year based assessments.
Study selection and eligibility criteria
We included original peer reviewed reports of observational
studies and clinical trials if published in full text or if we had
full access to all original data and protocols. We excluded
studies that were published only as abstracts or conference
reports.Weconsideredreportsthatevaluatedtheassociationof
reduced function and increased function genetic variants of
CYP2C19 with the occurrence of clinical outcomes in patients
with established coronary artery disease who were treated with
clopidogrel. Two researchers (DT and TB) independently
retrieved studies. The strength of agreement was measured by
Cohen’s κ coefficient with approximate standard errors,
21 with
κ=0.41-0.60 indicating moderate agreement, 0.61-0.80 good
agreement, and ≥0.81 representing very good agreement.
22
Disagreements were resolved by consensus.
Clinical eligibility criteria and outcome
definitions
Eligible studies were conducted in unrelated men and women
(aged≥18)ofanyethnicitywithaclinicalpresentationofstable
anginapectorisoracutecoronarysyndromewhowerescheduled
for administration of a loading dose of at least 300 mg
clopidogrelandsubsequentmaintenancetreatmentwith75-150
mg clopidogrel a day for at least three months. For eligibility,
studies must have reported follow-up data for at least 30 days
after entry (inclusion or randomisation) of participants. We
included studies if they provided absolute numbers of the
cumulativeincidence(firstoccurrenceduringfollow-up)ofthe
clinicalefficacyendpoints:majoradversecardiovascularevents
or fatal or non-fatal stent thrombosis.
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RESEARCHThe primary definition of major adverse cardiovascular events
wasthecompositeofdeathfromcardiovascularcauses,non-fatal
myocardial infarction, and non-fatal stroke or the composite of
death from any cause, non-fatal myocardial infarction, and
non-fatal stroke as evaluated by universal clinical guidelines.
Othereligibledefinitionsweredeathfromcardiovascularcauses
andmyocardialinfarction;deathfromanycauseandmyocardial
infarction; death from cardiovascular causes; and fatal and
non-fatal myocardial infarction. We required that the
components subsumed under the definition of major adverse
cardiovascular events were sensitive and unbiased measurable
events of the same underlying disease process. We excluded
studies reporting only all cause mortality because of the high
likelihood of bias by events without an underlying
cardiovascular cause. Studies reporting only composite end
points, including the clinician driven proxy outcomes of
revascularisation or admission to hospital, were excluded
because of uncertainties about precision, reproducibility,
correlationwithclinicalendpoints,theuseofnon-standardised
definitions, and a high risk of reporting bias.
23 24
Studies of patients who underwent percutaneous coronary
interventionandreportingdefinitestentthrombosiseventswere
eligible if the stent thrombosis was evaluated according to the
definitionfromtheAcademicResearchConsortium.
25Probable
stent thrombosis was considered only if definite and probable
stentthrombosiswerereportedasacompositeoutcome.Possible
stent thrombosis was not considered.
Genetic eligibility criteria
For unambiguous determination, polymorphisms of CYP2C19
needed to be designated by their NCBI dbSNP identifiers (“rs
numbers”), their nucleotide exchange, or their common
harmonised star allele nomenclature. We considered reports on
the loss of function (reduced function) variants CYP2C19*2
(rs4244285), CYP2C19*3 (rs4986893), CYP2C19*4
(rs28399504), CYP2C19*5 (rs56337013), CYP2C19*6
(rs72552267), CYP2C19*7 (rs72558186), or CYP2C19*8
(rs41291556), and the gain of function variant CYP2C19*17
(rs12248560). The variant gene carrier status was required to
be given as the distribution of genotypes among patients with
and without the outcome event or as the number of individuals
carrying at least one loss of function or gain of function allele.
Studies reporting associations with a loss of function variant
were eligible if they had genotyped at least the CYP2C19*2
allele because it accounts for more than 95% of the loss of
function allele carrier status in white and black African
populations and for more than 75% in Asian populations.
26
Genetic model assumptions
Pharmacokinetic studies using different CYP2C19 substrates
indicateanadditiveordominantmodeofinheritanceoftheloss
offunctionmetabolisertrait,showingeitheraperalleledecrease
in enzymatic activity
27 or a similar drop of activity in carriers
of one or two loss of function variants compared with
non-carriers.
28 29Pharmacokineticstudiesassessingthemetabolic
activity of CYP2C19 in relation to the gain of function
CYP2C19*17 variant likewise indicate either additive
inheritance with a per allele increase in activity between *1/*1,
*1/*17, and *17/*17 carriers
30 or dominant inheritance with a
similar gain of the enzymatic activities in carriers of one or two
*17 alleles compared with wild type *1/*1 carriers.
31
From the available mechanistic evidence we inferred that the
CYP2C19 metaboliser phenotype of clopidogrel is determined
by additive or dominant genetic models of inheritance and that
these models also apply to the associations of CYP2C19 with
clinical events. We chose dominant genetic models to quantify
theeffectsizeineachstudybycomparingthegenotypecontrasts
of carriers with one or two variant alleles with non-carriers of
the variant alleles because dominant or additive models have a
similar statistical power,
32 genotype contrasts are more directly
relevant at the individual and the clinical level compared with
allele contrasts obtained from additive models, and allele
contrasts could not be extracted from all studies.
Interaction between loss of function and gain
of function polymorphisms
Except for one study,
19 all association studies modelled loss of
function and gain of function polymorphisms independently of
each other, implying complete equilibrium of linkage and
absence of functional interaction. An examination of the
polymorphic loci of the CYP2C19 gene in white populations
(HapMap-CEU database, Haploview, version 4.2 software,
Broad Institute, Harvard, MA, USA) showed a low pairwise
correlation coefficient (r
2=0.047) between the most common
loss of function polymorphism (*2) and the gain of function
polymorphism *17. This excludes a substantial interaction
between the single nucleotide polymorphisms at the haplotype
level but entails the risk of interaction at the phenotype level.
In single locus assessments of the CYP2C19*2 variant, about
a quarter of all individuals classified as *2 allele carriers and
about half of those classified as non-carriers were harbouring
at least one *17 allele.
18 In turn, in single locus analyses of the
CYP2C19*17variant,about20%ofpeopleclassifiedascarriers
of the *17 allele and about 35% of those classified as
non-carriers were harbouring at least one *2 allele.
18
Pharmacokinetic analyses
31 33 and pharmacodynamic platelet
response studies
17 suggest that the metaboliser phenotypes of
mixed carriers of *2 and *17 alleles are comparable with
individuals who are homozygous carriers of the wild type (*1)
alleles at both loci. Therefore, the independently analysed
associations of loss of function and gain of function single
nucleotide polymorphisms with clinical outcomes are probably
systematically distorted by the counteracting metaboliser trait.
Thisdoesnotnecessarilyinvalidatetheassociationsorincrease
the heterogeneity between studies, if it is assumed that a
proportional bias applies to all studies. Because of higher
frequencies of misclassified phenotypes among non-carriers of
a certain variant allele, compared with the respective carriers,
however, a trend towards overestimation of the single locus
effect sizes is expected.
The rare loss of function variant loci CYP2C19*3-*8 are found
withinthesamelinkagedisequilibriumblockwiththe*2variant.
The pairwise correlation coefficients (r
2≤0.019) indicate that
their alleles assort independently of the *2 allele. Under the
assumption of stochastic independence we pooled the data on
loss of function alleles and analysed the combined values as
data derived from a single bi-allelic loss of function locus.
Data collection process and extracted items
For standardisation of data extraction we adopted the Cochrane
Consumers and Communication Review extraction template,
modified it by the recommendations in the HuGE Review
Handbook for abstracting genetic information, pilot tested five
randomly selected included studies, and refined it accordingly.
Two investigators independently extracted data from the
included studies. Inconsistencies were resolved by consensus.
Extracteddataincludedstudyidentifiers(thefirstauthor’sname,
year of publication, country or geographical origin of
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RESEARCHinvestigation, single or multicentre study); characteristics of
studydesign(typeofstudy,prospectiveorretrospectivedesign,
follow-up); characteristics of study participants (including
diagnosis and procedural characteristics at study entry,
demographiccharacteristics(number,sex,age,BMI(bodymass
index),andcardiovascularriskfactors(smoking,hypertension,
dyslipidaemia, diabetes mellitus)); characteristics of study
intervention(loadingdoseofclopidogrel,durationoftreatment,
comedicationwithaspirin);outcomemeasures(typeandnumber
of events, carriers with loss of function or gain of function
alleles) (table 1).
Weincludeddatafrommultiplepublishedreportsfromthesame
study population only once. We used only the data from the
initial report, and, in the case of overlapping samples, we used
the data of the largest follow-up study. If a report referred to a
previouspublicationforthedescriptionofstudydesign,setting,
and patients’ characteristics, we extracted these data. Missing
data for one study
34 were extracted from a subsequent
meta-analysis
14 conducted by the same corresponding author.
Toavoidtheriskofretrievalbiaswedidnotcontacttheoriginal
investigatorsformoredetailedinformationwhenwewereunable
to obtain complete data and protocols from all studies or to
check accurateness and reliability of the obtained data.
Methods for assessing the risk of bias in
individual studies
Toexploretheriskofbiasinindividualstudies,weinvestigated
indicators general to the quality of epidemiological studies and
specific to the quality of genetic association studies.
35 36 We
extracted quality information on loss to follow-up, funding
sources, comparability of groups (demographic and clinical
homogeneity between groups with and without outcome,
demographic and clinical homogeneity between carriers and
non-carriers of the allele of interest, absence of population
stratification (ethnic homogeneity)), reliability and validity of
phenotypeassessment(useofstandardiseddefinitionsofdisease
phenotypes, blinding of clinical outcome assessors to patients’
genetic information), and reliability and validity of genotype
assessment(consistencyofobservedgenotypefrequencieswith
the Hardy-Weinberg equilibrium, use of an appropriate
genotypingmethod,highcallrate,blindingofinvestigatorswho
performed genotyping to clinical outcome).
Additionally, in adopting the guidelines of the Cochrane
Handbook for Systematic Reviews of Interventions, we graded
the methodological quality of the selected studies with a
summaryscoreusingtheNewcastle-Ottawaqualityassessment
scale.
37 We applied a modified scale (adapted for genetic
association studies), awarding a maximum score of 8, with one
pointeachforrepresentativenessoftheexposedgroup(carriers
of the genotype of interest) for the underlying population;
selection of the unexposed group (non-carriers) from the same
population as the exposed individuals; adequate measurement
of exposure; adequate ascertainment of the absence of the
outcome of interest at begin of the study; demographic and
clinicalcomparabilitybetweengroups(carriersandnon-carriers
ofthegenotype);appropriatemeasurementofoutcome;adequate
length of follow-up; and completeness of follow-up. Study
quality was considered to be good when the score was ≥6 and
poor to moderate when the score was <6. Two investigators
independentlyscoredquality,andtheinter-rateragreementwas
determined by the κ statistic.
Consistency of the observed genotyping frequencies with the
Hardy-Weinberg equilibrium provides an overall (albeit
insensitive and non-specific) indication for the absence of any
strong bias by the selection of patient groups, population
stratification,orgenotypingerrors.Wecheckeddeparturefrom
Hardy-Weinberg equilibrium using Fisher’s exact test
38 instead
of the χ
2 test reported in the individual studies as it yields
increasedstatisticalpower.Forthecohortstudiesandthegenetic
subgroupanalyses,testingonHardy-Weinbergequilibriumwas
performed in the whole population, and for the case-control
study in the control group. We considered that significant
departure from Hardy-Weinberg equilibrium (P<0.05)
necessitated a correction of individual risk estimates.
35
Summary effect measures and sample size
estimation
Wecalculatedcrudeunadjustedoddsratiosand95%confidence
intervals for each study based on genotype contrasts of a
dominant model comparing heterozygous and homozygous
genotypes of the minor allele with homozygous genotypes of
the major allele. As primary summary effect estimates we
calculated summary odds ratios and 95% confidence intervals
accordingtotheDerSimonianandLairdrandomeffectsmodel,
which utilises weights that incorporate variance within and
between studies. In addition, we calculated the fixed effects
summary estimates according to the Mantel-Haenszel method,
which includes only variance within studies. Fixed effects
meta-analysis assumes that the genetic effects are the same
across all studied populations. Random effects calculations
assume that the genetic effects might vary across populations
becauseofgenuinedifferences(suchaspopulationspecificgene
environment or gene-gene interactions) or differential biases
(such as population stratification; genotyping error; phenotype
misclassification; and population differences in correlation of
clinicalphenotypes,correlationbetweenmolecularandclinical
phenotype, and linkage disequilibrium of gene variants).
Anticipatingheterogeneitybetweenstudiesinmeta-analysesof
geneticassociationstudies,randomeffectsmodelsaregenerally
the preferred frequentist approach compared with fixed effect
models.
39-41 In the presence of high variance between studies,
however, the random effects analysis has considerably less
powertorejectthenullhypothesisofnoassociation.Bycontrast,
random effects models give relatively more weight to smaller
studies, which involves the risk of generating higher summary
estimates in the presence of bias from small study effects.
Therefore, we have presented both random and fixed effects
analysis. P<0.05 indicates a nominally significant overall
association (according to the z test statistic for the null
hypothesis of no association (odds ratio 1)).
To estimate the total sample size needed to be included in a
meta-analysistodetectasignificantassociationatlowsummary
oddsratios,weperformedMonte-CarlosimulationsusingPBAT
software, version 3.61.
42 For a dominant genotype contrast, to
detect a summary odds ratio of 1.15 (the threshold for
epidemiologicalcredibility
43)atasignificancelevelα=0.05with
apowerof0.80forcumulativeeventratesintherangeof1-10%
andminorallelefrequenciesintherangeof15-25%,therequired
sample size was about 8000-9000, and to detect an odds ratio
of 1.20 it was about 4500-5000 (based on 10 000 simulations
each).
Heterogeneity measures
The presence of heterogeneity between studies was explored
with the Cochran’s Q statistic, which is the weighted sum of
squares of the deviations of individual study odds ratios from
the Mantel-Haenszel summary odds ratio. The statistic follows
a χ
2 distribution with k−1 degrees of freedom (where k is the
number of studies); P<0.10 indicated significant heterogeneity.
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RESEARCHThe extent of variance between studies was estimated by the τ
2
metric. The percentage of total variance attributable to
heterogeneity between studies was quantified with the I
2 metric
and its approximate 95% confidence intervals (where
I
2=((Q−(k−1))/Q)×100%). I
2 is independent of the number of
studies and—in contrast with Q and τ
2—allows comparison
across different meta-analyses.
44 Values of I
2 <25%,
≥25%-<50%, and ≥50% were considered to represent low,
modest, and large heterogeneity, respectively. Both Q and I
2,
however,haveonlylowstatisticalpowertodetectheterogeneity
with small numbers of studies
45 and provide no information
about the causes of heterogeneity. Hence, we performed
additional prespecified heterogeneity and sensitivity analyses.
Formal evaluations required that at least four studies were
included in the meta-analysis.
Assessment of bias across studies
Inconsistency in replication is an important issue in genetic
association. The first studies often suggest a stronger genetic
effect than is found by subsequent studies.
46 To assess the
replication validity in the meta-analyses we compared the odds
ratio of the first published studies with the random effects
summary odds ratios without the first studies using the z test
statistic, with P<0.05 indicating a significant inconsistency in
replication.
35 To explore the evolution and robustness of the
summary effect estimates over time, we conducted cumulative
and recursive cumulative meta-analyses. In cumulative
meta-analysis, the random effects summary odds ratios are
calculated with publication of each new study. In recursive
cumulativemeta-analysis,theratioofthecumulativeoddsratios
in year n+1 to year n is calculated.
47 These analyses facilitate
the identification of early extreme contradictory estimates in
geneticassociationsandofpotentialtimelagbiasresultingfrom
a more rapid publication of studies with significant results
compared with studies with non-significant results.
35
Toassesspotentialbiasfromsmallstudyeffectsweconstructed
funnel plots displaying the log odds ratios of individual studies
on the horizontal axis and the standard errors of the log odds
ratios (precision) on the vertical axis. Funnel plot asymmetry
is a graphical means of indicating whether effect estimates of
small studies differ from those in larger studies,
48 but visual
inspection is an unreliable method to detect bias. We carried
out formal statistical assessment of funnel plot asymmetry with
the Harbord-Egger regression test, which yields lower false
positive and false negative rates when applied to dichotomous
outcomes compared with the traditional Egger regression test
or the Begg-Mazumdar rank correlation test.
49 50 P<0.10 was
assumed to indicate a significant difference of the precision in
large versus small studies. For more specific evaluation of the
presence and extent of publication bias we used the
non-parametric trim and fill method according to Duval and
Tweedie,
51 which imputes missing studies in the funnel plot
based on symmetry assumptions.
Sensitivity analyses
Weperformedaprespecifiedcombinatorialexclusionsensitivity
analysis to identify the individual studies or clusters of studies
that provide the strongest contribution to the heterogeneity of
the meta-analysis.
52 Potential differences in the main
characteristics of excluded studies in comparison with the
remainingstudieswereinvestigated(consideringthestructured
PICOS information of the Cochrane Handbook for Systematic
Reviews, chapter 5).
Grading the evidence of meta-analyses
Reliable and valid instruments for evaluating the quality of the
evidence derived from systematic reviews and meta-analyses
are essential for developing transparent and unbiased clinical
recommendations and avoiding implicit subjectivity. For
judgment of the strength of the meta-analysed evidence for
recommendations we applied the GRADE methods, proposed
by WHO for producing practice guidelines.
53 54 To evaluate the
quality of evidence with specific regard to genetic topics, we
used the Venice consensus criteria
43 for rating the cumulative
epidemiologicalevidenceofmeta-analysesofgeneticassociation
studies that yield significant (P<0.05) summary estimates.
Within the GRADE evaluation process observational studies
are basically considered to present low quality of evidence.
AccordingtotheGRADEhandbook,version3.2,andpragmatic
instructions to guide the grading process
54 judgments on the
included studies are made with respect to the following five
criteria that lower the quality of evidence: limitations of
individual studies (risk of bias within a study); inconsistency
(heterogeneity of results across studies); indirectness of
evidence; imprecision (total number of events <300)
55; and
publication bias. Studies not downgraded for any reason are
judged for three factors that increase the quality of evidence:
dose-response gradient (gene-dose effect); large magnitude of
effect (relative risk >2.0 or <0.5); and reduction of effect by all
plausible biases present (potential underestimation of effect).
TheVeniceconsensuscriteriaassignthreelevelsfortheamount
of evidence, the consistency of replication, and the protection
from bias. For amount of evidence, grade “A” is assigned when
thetotalnumberofminorallelesofcasesandcontrolscombined
in the meta-analyses exceeds 1000, “B” when it is between 100
and 1000, and “C” when it is less than 100. For replication and
consistency, grade A is assigned for I
2 <25%, B for I
2 25-50%,
and C for I
2 >50%. For protection from bias, grade A implies
that there is probably no bias that can affect the presence of the
association, grade B that there is no demonstrable bias but
important information is missing for its appraisal, and grade C
that there is evidence for potential or clear bias that can
invalidate the association. Specifically, whenever the summary
odds ratio deviates less than 1.15-fold from null association
(oddsratio=1),occultpublicationandselectivereportingbiases
alonemightinvalidatetheassociation,regardlessofthepresence
orabsenceofotherbiases,andthereforeagradeofCisassigned.
When the summary odds ratio is ≥1.15-fold from null
association,agradeofCisassignedwhenasignificantmodified
regression test suggests the possibility of bias or when the
association is no longer nominally significant on exclusion of
the initial study or of studies violating the Hardy-Weinberg
equilibrium.Thecompositeepidemiologicalcredibilityisrated
as“strong”ifthreeAgradesareassigned,“moderate”ifatleast
one B grade but no C grades are assigned, and “weak” if a C
grade in any of the three assessment criteria is assigned.
The grading was done independently by two investigators and
repeated by a third investigator if disagreement occurred.
Statistical software programs
The statistical analyses were performed with PASW version
18.0.1(SPSS,Il,US),CochraneReviewManager5.0(Cochrane
Library Software, Oxford, UK), and MIX version 1.7
(Department of Medical Informatics of Kitasato University,
Japan).
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RESEARCHResults
Study selection
We identified a total of 4203 reports in the initial search (fig 1)
and removed 1114 duplicate publications. We also excluded
2847non-relevantrecordsbasedonscreensoftitlesorabstracts.
Fulltextarticleswereretrievedfor242publicationsandassessed
for eligibility. We then excluded 228 articles, mainly because
they reported only pharmacodynamic or pharmacokinetic
associations with CYP2C19 or associations of inhibitors of
CYP2C19 with clinical outcomes. The genetic substudy of the
randomised controlled ACTIVE A trial was excluded because
it was conducted in patients with atrial fibrillation and did not
provideageneticsubgroupanalysisforpatientswithadditional
coronary artery disease at baseline.
19 Three studies were
excluded because the outcome assessment did not meet the
eligibilitycriteria;onestudydisplayedonlyallcausemortality.
56
One study reported only the combined end point of
cardiovascular death, myocardial infarction, ischaemic stroke,
stent thrombosis, revascularisation, and admission to hospital
for coronary ischaemia.
57 One study compared genotype
frequencies in cases with untreated control subjects.
58 We did
notconsiderfourpotentiallyeligiblestudiesthatwerepublished
only in abstract form or as conference proceedings.
59-62
Overall,weidentified14articlespublishedinEnglishinvolving
15observationalstudiesorgeneticsubstudiesfromrandomised
controlled trials that met the inclusion criteria and included
these in the systematic review.
18-20 34 63-72
The κ statistic indicated a very good agreement between the
abstracting investigators (κ 0.84; SE 0.07).
Characteristics of included studies
Twelve studies with a total of 18 529 participants examined the
association of a reduced function variant of CYP2C19 with
major adverse cardiovascular events,
18-20 34 63-68 70 72 and nine
studiescombining19328participantsexaminedtheassociation
with stent thrombosis.
18 20 34 66-68 70 71 Five studies with a total of
9128 participants investigated the association of the gain of
function variant CYP2C19*17 with major adverse
cardiovascular events,
19 20 65 69 70 and three studies
20 69 70 with
4434 participants examined the association with stent
thrombosis.Table1presentsthecharacteristicsoftheindividual
studies.
Design
Most studies (n=10) were retrospective genetic analyses of
studies that were not primarily designed to evaluate genetic
association.
18 19 34 63 65-69 71 Nine studies were cohort
studies,
20 63-66 68-70 72 four were substudies of randomised
controlled trials,
18 19 34 67 one was a prospective case-cohort
study,
20 and one was a case-control study.
71 Eight studies
involved multiple centres.
18-20 34 65 66 71
Participants
All studies included participants of both sexes; around 60-90%
were men. In 14 studies the mean age at entry was over 60. In
one study participants were younger (average age 40) and had
a lower prevalence of hypertension and diabetes mellitus.
66
Intervention
Most studies (n=13) noted that patients received a loading dose
of clopidogrel (usually 300 or 600 mg) at occurrence of the
index event or at the index procedure.
18-20 34 63-65 67-70 72 The
maintenance dose at discharge from hospital was 75 mg a day
inallstudies.Morethan90%ofpatientsinallstudieswerealso
treated with aspirin (75-325 mg a day). The follow-up periods
ranged from 1 to 35 (median 12) months.
Outcomes
Six of 13 studies reporting the incidence of major adverse
cardiovascular events met the primary outcome definition,
constitutingthecompositeof(cardiovascularorallcause)death,
myocardial infarction, and stroke
18-20 34 65 70; the other studies
reported components of the primary definition. Seven of 10
studies that assessed stent thrombosis reported definite
events
18 20 66-68 71; three assessed the composite of definite and
probable events.
34 69 70 The cumulative incidence of major
adverse cardiovascular events in the population based studies
ranged from 3.0% to 13.3% and of stent thrombosis from 0.5%
to 2.2%. The frequency of the *2 allele or of combinations of
the loss of function alleles lay between 10.5% and 18.8%, and
the allele frequency of the *17 variant was between 20.2% and
22.9%.
Risk of bias in individual studies
The risk of bias in the included studies was assessed with a
standardapproachwithpredefinedcriteria(table2).Thegeneral
methodological quality of the studies judged on the modified
Newcastle-Ottawa scale was rated moderate to good (scores of
5-8). The agreement between raters in the awarded scores on
the8pointscalewasconsideredgood(12agreementsandthree
disagreements by 1 point; κ 0.69, SE 0.16). Potential risks of
individual bias with respect to general epidemiological topics
included missing information about loading dose (two
studies
66 71), no pre-fixed follow-up periods (two studies
66 72),
high rates of loss to follow-up (one study
72), cessation of
clopidogrel maintenance treatment before end of follow-up or
missing information about duration of treatment (10
studies
18-20 34 63-66 69 70), no explicit criteria for adherence to
treatment (13 studies
18 19 34 63-72), and funding by industry or
healthcare providers (five studies
18 19 34 65 69). One study assessed
incidentmyocardialinfarctioninasampleofpatientsaged18-45
who were not representative for a population of cardiovascular
patients.
66
The quality of the individual studies with respect to specific
genetic indicators showed larger deficiencies: five studies did
not assess the comparability of baseline demographic and
clinical characteristics between carriers and non-carriers of the
CYP2C19 genotype of interest,
18 19 65 68 71 12 studies showed
differences in characteristics between groups with and without
outcome or did not perform group comparisons.
18 19 34 63-69 71 72
This implies the possibility that the association with CYP2C19
could be confounded by variations in genetically or
non-genetically determined factors that were associated with
the outcome. Eight studies did not determine the ethnicity of
participants, which introduces the risk of population
stratification, although this is less likely to occur in studies
conducted in Europe than in more heterogeneous American
populations.
63-65 67-71 All studies (except for one
64) used
standardised definitions for assessment of outcomes, and in
moststudies(exceptforthree
64 66 70)theoutcomeassessorswere
explicitly blinded or unaware (retrospective analysis) to the
genotyping result of the individuals, which minimised the risk
of misclassification of diseases. Only three studies, however,
stated that the genotyping was done blinded to the outcome
status of patients, which does not ensure an unbiased
assessment.
20 69Allstudiesreportedhighcallratesofgenotyping
(that is, a high proportion of samples in which genotyping
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RESEARCHprovided an unambiguous reading). This indicates a low extent
of missing data on genotyping. Only five studies explicitly
described the implementation of quality checks or validation
rules to reduce genotyping errors.
20 67 69 70 Such errors are not
uncommon and can distort the robustness of association
measures.
73 Except for one study that did not provide genotype
frequenciestoallowtesting,
72therewasnosignificantdeparture
from the Hardy-Weinberg equilibrium. All studies assumed
dominantorcodominantmodelsfortestingofgeneticcontrasts,
but none gave a biological reason for the choice of the model
and no adjustments for multiple comparisons were performed.
Moreover, the studies reported different effect measures with
or without adjustments for potential covariates. To yield
consistency and comparability between effect estimates, we
calculated the unadjusted odds ratios for each study.
Results of individual studies and synthesis
of results
The forest plots show the odds ratios with 95% confidence
intervals for each study. They also incorporate the proportions
of events in specific groups and the weighting factors for the
summary effect estimates and present measures of consistency
between studies (Q, I
2, τ
2) and results of a significance test of
the overall effect.
Associations with loss of function CYP2C19
variants
Forcomparisonofcarriersofatleastonereducedfunctionallele
of CYP2C19 with non-carriers the unadjusted individual odds
ratiosofmajoradversecardiovasculareventsweresignificantly
higher in three of 12 studies,
34 66 68 lower in one study,
70 and not
significantly different from null effect in eight (fig2).
18-20 63-65 67 72
The odds ratios of stent thrombosis were positively associated
with the reduced function CYP2C19 allele carrier status in four
of nine studies,
34 66 67 71 whereas five studies showed no
significant association.
18 20 68 70
The random effects summary odds ratio for major adverse
cardiovascular events was 1.11 (95% confidence interval 0.89
to 1.39; P=0.36) and the corresponding fixed effects summary
odds ratio was 1.07 (0.96 to 1.19; P=0.24), with heterogeneity
measures: Q=30.1 (df=11, P=0.002); I
2=63.4% (31.9% to
80.3%); τ
2=0.075. The random effects summary odds ratio for
stentthrombosiswas1.77(1.31to2.40;P<0.001),andthefixed
effects summary odds ratio was 1.67 (1.34 to 2.08; P<0.001)
withQ=11.8(df=8,P=0.16);I
2=32.3%(0%to68.8%);τ
2=0.063.
Associations with gain of function CYP2C19*17
variant
None of the individual studies showed a significant positive or
negative association of major adverse cardiovascular events or
stentthrombosiswithCYP2C19*17(fig3).Therandomeffects
summary odds ratio for major adverse cardiovascular events
was 0.93 (0.75 to 1.14; P=0.48), and the fixed effects summary
odds ratio was 0.90 (0.78 to 1.04; P=0.15); heterogeneity
statisticswere:Q=7.3(df=4,P=0.15);I
2=45.4%(0%to80.0%);
τ
2=0.025. The random and fixed effects summary odds ratios
of stent thrombosis were identical: 0.99 (0.60 to 1.62; P=0.96),
and indicators of heterogeneity were: Q=0.06 (df=2, P=0.97);
I
2 =0.0% (0% to 89.6%); τ
2 =0.00.
The total sample size of the non-significant meta-analyses was
lower compared with the meta-analysis showing a significant
outcome. The simulations of the sample size needed to detect
agivenvalueofdominantcontrastoddsratio,however,indicate
that all meta-studies had sufficient power to identify clinically
noteworthy associations with odds ratios ≤1.20.
Risk of bias across studies
Heterogeneity
The Q statistic and the point estimate ( I
2) indicate the presence
of high heterogeneity between studies in the meta-analysis of
studies examining the association of CYP2C19 loss of function
alleles with major adverse cardiovascular events, whereas the
other meta-analyses did not exceed the conventional levels for
significant heterogeneity (P<0.10 or I
2≥50%). In all
meta-analysistheupper95%confidenceintervalofI
2exceeded
the threshold of large heterogeneity (I
2≥50%). We cannot
therefore exclude the presence of considerable heterogeneity
across the studies,
45 which necessitates further assessments of
heterogeneity. The meta-analysis of CYP2C19*17 and stent
thrombosis included only three studies, which precluded the
application of formal statistical methods for evaluation of
heterogeneity.
Replication validity and evolution of summary
estimates in time
The z statistic for comparison of the odds ratio of the first
published study with the random effects pooled odds ratio of
the remaining studies was not significant for the associations
of major adverse cardiovascular events with loss of function
variants (z=−1.28, P=0.20) or the gain of function variant
(z=−1.38, P=0.17). There was, however, significant diversity
withintheassociationsofstentthrombosiswithlossoffunction
variants between the initial (almost simultaneously published)
studies of Mega et al
34 and Collet et al
66 and the subsequent
studies (z=2.39, P=0.017). Correspondingly, the cumulative
meta-analysis for comparison of the loss of function variants
with stent thrombosis showed a trend of decreasing strength of
association as information accumulated. Recursive cumulative
meta-analysis showed a significant relative change in the
cumulative pooled odds ratio between information published
in 2010 and information published in 2009 (0.395, z=−3.093,
P=0.002). This suggests that the relation between the loss of
function CYP2C19 genotypes and stent thrombosis is not
sufficiently established by the accumulating evidence that the
change in odds ratio could stabilise over time. No such time
instabilities were observed in cumulative meta-analyses of the
other associations. At no point in the acquisition of additional
information was a significant cumulative odds ratio obtained.
For the association of loss of function variants with major
adverse cardiovascular events, the recursive cumulative
comparison of odds ratios of studies published in 2010 with
thosepublishedbeforeshowedanon-significantrelativechange
of 0.722 (z=−1.337, P=0.181). It was not possible to apply
recursive cumulative meta-analysis to the associations with
CYP2C19*17 as all included studies (except for one
65) were
published in 2010.
Small study effects and publication bias
Figure 4 shows the funnel plots of the meta-analyses. In the
funnel plot based on the results of 12 studies on the effect of
lossoffunctionvariantsonmajoradversecardiovascularevents,
twostudies
66 70wereoutsidetheexpected95%confidencelimits.
In the corresponding funnel plot of nine studies on the effect of
loss of function variants on stent thrombosis, one study was
outside the expected 95% confidence limits.
66 This asymmetry
indicates the possibility of heterogeneity by small studies or
selection bias. The modified Egger regression test indicated a
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function variants with stent thrombosis (t=1.93, P=0.095), and
thetrimandfillanalysissuggeststhattwostudiesweremissing.
The adjusted random effects summary odds ratio of 1.55 (1.10
to2.20;P=0.014)obtainedaftersymmetricallyfillingthefunnel
plot supposes that the strength of the association with stent
thrombosis is overestimated (by 14%) because of unpublished
studies. The modified Egger test was non-significant for the
other associations yielding t=0.76 (P=0.46) for comparisons of
loss of function variants with major adverse cardiovascular
events and t=1.48 (P=0.24) for comparisons of the gain of
function variant with major adverse cardiovascular events.
Accordingly, the trim and fill analysis showed no missing
studies.
Sensitivity analysis
Targeting for a minimum I
2 below the 50% threshold in the
meta-analysis of loss of function variants and major adverse
cardiovascular events, the combinatorial algorithm led to
exclusion of the studies of Collet et al
66 and Tiroch et al
70
(representing outliers in the funnel plot), giving I
2=40.9% and
a residual odds ratio of 1.09 (0.92 to 1.30; P=0.30). To achieve
the minimal I
2 value <25%, four studies
34 65 66 70 had to be
omitted,resultinginI
2=18.8%andavirtuallyunchangedresidual
odds ratio of 1.09 (0.93 to 1.29; P=0.29). In the meta-analysis
of loss of function variants and stent thrombosis, exclusion of
the study of Collet et al
66 decreased I
2 below the requested 25%
threshold,leadingtotheminimumfinalI
2of8.6%andreducing
the residual odds ratio (by 9%) to 1.61 (1.26 to 2.07; P<0.001).
In the meta-analysis of CYP2C19*17 and major adverse
cardiovascular events, targeting for minimum values of I
2 and
Q, the studies of Simon et al
65 and Pare et al
19 were excluded,
yielding I
2=0% (Q=0.6) and a residual odds ratio of 1.13 (0.90
to 1.41; P=0.29). In none of the meta-analyses did the nominal
significanceornon-significanceofthesummaryeffectestimates
change on exclusion sensitivity analysis.
Grading of meta-analyses
Following the GRADE algorithm, we downgraded the quality
of the evidence of studies investigating major adverse
cardiovascular events in relation to loss of function genotypes
from low to very low for heterogeneity between studies that
was not explained by study design, differences between
populations or interventions, or length of follow-up. We
downgraded the meta-analysis of the associations of stent
thrombosis with loss of function alleles for evidence of
publication bias suggesting a systematic overestimation of the
harmful effects of clopidogrel in loss of function allele carriers.
Themeta-analysisoftheassociationsbetweenstentthrombosis
and CYP2C19*17 was downgraded because of imprecision
(total number of events <300). By contrast, the meta-analysis
of associations between major adverse cardiovascular events
and CYP2C19*17 was not affected by confounders that were
sufficient to downgrade the quality of evidence, but the overall
judgment remained low as none of the criteria leading to
upgrading in the quality of evidence were met. The grading of
the quality of the epidemiological evidence as low or very low
thus classifies any estimate of effect as uncertain or further
researchaslikelytohaveanimportantimpactontheconfidence
in the estimates.
When we applied the Venice criteria for the assessment of
cumulative evidence in genetic association studies with
nominally significant summary effect estimates, the
meta-analysis of the association of stent thrombosis with loss
of function variants was graded as A for criterion 1 (amount of
evidence>1000minorallelesincombinedstudies)andasBfor
criterion2(consistencyofreplicationI
2=25-50%).Forcriterion
3 (protection from bias) we assigned grade C because the
modified Egger regression test suggested the presence of
publication or small study effects bias. Based on the C grading,
theoverallepidemiologicalcredibilityofthismeta-analysiswas
rated as “weak.” There were no disagreements between the two
raters (DT and TB) in the judgments according to GRADE and
Venice methods.
Discussion
Principal findings and relation to other studies
CYP2C19 gene polymorphisms do not influence the clinical
efficacy of clopidogrel used to prevent thromboembolic events
in patients with ischaemic cardiovascular diseases. We
summarised the existing data on the association of the carrier
statusofvariantallelesassociatedwithlossandgainoffunction
with the incidence of major adverse cardiovascular events or
stent thrombosis in patients receiving clopidogrel antiplatelet
treatment. We retrieved 15 studies that met the prespecified
eligibility criteria using a systematic search strategy. The
summary odds ratios derived by adopting a dominant genetic
model indicate that carriers of at least one loss of function allele
showanincreasedriskofstentthrombosis.Thesummaryeffect
estimates were not significant for the association of major
adverse cardiovascular events with carrier status for the loss of
function allele and for the associations of major adverse
cardiovasculareventsorstentthrombosiswithcarrierstatusfor
the gain of function CYP2C19*17 allele.
The systematic examination of potential sources of bias within
the individual studies, the risk of misclassified phenotypes, and
the assessment of inconsistencies between studies that used
heterogeneity tests and sensitivity analyses indicate that all
meta-analyses are affected by confounders that tend to weaken
the strength or presence of the associations. Specifically, the
association of stent thrombosis with loss of function genotypes
was subject to bias from small study effects and to interaction
with publication year. Adjustment for these quality modifiers
tended to abolish the association. By using consensus grading
systems to assess the cumulative evidence, all meta-analyses
had low levels of epidemiological credibility or quality. We
infer that, at the current state of accumulated information, there
is no sufficiently robust and consistent evidence that CYP2C19
represents a strong susceptibility gene modifying the clinical
efficacy of clopidogrel.
Ourfindingsdisagreewiththeresultsofpreviousmeta-analyses,
which reported a significant higher risk of major adverse
cardiovascular events in carriers of the loss of function
CYP2C19 gene variants and a considerably higher strength of
theassociationbetweenstentthrombosisandthelossoffunction
variants. Two factors could explain the discrepancies. Firstly,
previous meta-analyses included only those studies published
before2010thatgenerallyshowstrongereffectscomparedwith
thesubsequentlypublishedstudies.Secondly,weextractedonly
the data of such prespecified clinical events that conformed to
unbiasedandstandardiseddefinitions,excludingcliniciandriven
or less accurately defined events or outcomes with a high risk
of aetiological confounding from genetic heterogeneity.
The lack of significance, inconsistency of results, or low
epidemiological credibility do not rule out the presence of a
true causal association with CYP2C19. A causal involvement
of CYP2C19 in the bioactivation of clopidogrel and thus its
clinical response, however, is not supported by stringent and
unequivocal biological data. A recent metabolomic analysis,
20
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74 75 suggest that clopidogrel is
metabolised primarily by CYP3A isoenzymes, but not by
CYP2C19,toyieldtheintermediateproduct2-oxo-clopidogrel.
This is transformed into the active metabolite by hydrolysis not
involving cytochrome P450 enzymes.
Limitations of the study
Our systematic meta-analyses had several limitations. Firstly,
although we applied a highly sensitive search strategy for the
retrieval of potentially eligible studies, we cannot rule out that
some studies might have been overlooked. Secondly, we
excluded results from association studies existing only as
abstracts. This could have caused a disproportionate exclusion
ofsignificantornon-significantfindingsresultinginpublication
bias, but the incomplete data of abstracts entail uncertainties
anddidnotallowustoperformvalidityassessments.Moreover,
in line with our findings, the extractable data on major adverse
cardiovascular events from the four potentially eligible studies
that were available only as abstracts showed no significant
associationwithcarrierstatusfortheCYP2C19lossoffunction
or gain of function alleles.
59-62 Thirdly, differential genotype
dataforcarrierstatusforthelossoffunctionandgainoffunction
alleles were missing in most studies. Thus, the single locus
genotype contrasts were reported independently of each other,
which could have led to a systematic overestimation of effects
attheindividualstudylevel.Fourthly,unavailabilityofgenotype
for individual patients and demographic and clinical data in all
studies meant we could not carry out haplotype based analyses,
adjustment at the patient level for potentially confounding
covariates, or time to event analyses. This might have removed
theobservedheterogeneitybetweenstudiesbyeliminatingbias
and genuine diversity at the individual level. A meta-analysis
of the association between CYP2C19*2 and cardiovascular
eventscombiningindividuallyadjustedhazardratios,however,
yielded a similar magnitude of effect estimates and a similar
level of heterogeneity
14 compared with meta-analyses that
combined unadjusted odds ratios based on study level data.
11 13
Fifthly, in contrast with stent thrombosis, the classification of
major adverse cardiovascular events varied across studies and
the components of the event cluster were aetiologically diverse
and influenced by numerous covariates apart from platelet
activity. The composite of death, myocardial infarction, and
stroke,however,isacommonprimaryendpointinclinicaltrials
of coronary artery disease and shows considerable practical
relevance and high accurateness of diagnosis because of
standardised definitions. Sixthly, our analyses did not consider
cotreatmentwithCYP2C19inhibitorydrugs,specificallyproton
pump inhibitors, which could have confounded the genetic
associations. None of the individual association studies that
mentionedtheuseofprotonpumpinhibitors,however,observed
significantinteractionswithCYP2C19genotypes.
18 20 65 66 68 69 71 72
Also,ithasbeensuggestedthateffectsofprotonpumpinhibitors
on the platelet response to clopidogrel are independent of the
CYP2C19 allele carrier status
17 and that potential adverse
cardiovasculareffectsofprotonpumpinhibitorsarecompletely
independent of clopidogrel use.
76 77 Finally, the grading
instruments we used for assessment of epidemiological and
genetic quality of individual studies and of the overall
epidemiological evidence of the meta-analyses are based on
criteriathathavebeencreatedbyexpertconsensusbutthatneed
further prospective validation of their performance.
Implications for practice and future research
Summarised information from genetic association studies
indicates that CYP2C19 has no major impact on the clinical
efficacy of clopidogrel. There is no reliable and robust clinical
justification to apply personalised treatment with clopidogrel
tailored to CYP2C19 genotype.
Studies with a different design would be necessary to resolve
the uncertainties and produce satisfactory answers to the role
ofCYP2C19inclopidogrelactivity.Specifically,themolecular
mechanismslinkingCYP2C19activitytoclinicaleffectiveness
of clopidogrel should be explored in more detail. Moreover,
results of large scale randomised controlled clinical trials that
examine efficacy of clopidogrel in relation to the CYP2C19
allele carrier status would be less amenable to bias and could
provide more reliable evidence.
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RESEARCHTables
Table 1| Characteristics of included studies of effect of variants of the cytochrome P450 (CYP) 2C19 genotype on clinical efficacy of
clopidogrel
No (%) of participants with ≥1
allele; MAF
No (%) of
events
Clopidogrel
loading dose,
Cardiovascular
risk factors
Demographics
(mean (SD)
Diagnosis at
entry Design Study
treatment
duration;
aspirin
comedication
unless stated
otherwise)
Gain of
function
CYP2C19*17
Loss of function
CYP2C19 (at least
*2)
ND 245 (30.7%), (*2);
16.4%
MACE (death,
MI), 24 (3.0%)
600 mg, median
1 (range 1-6)
months (1
month for BMS,
6 months for
DES); 100%
aspirin
Smoking 10.9%,
hypertension 82.3%,
dyslipidaemia NR,
diabetes 24.8%
n=797, 78.0%
men, age 66.4
(9.1) years, BMI
27.7 (3.9)
Stable and
unstable angina
(ACS 27.4%, PCI
100%, DES
36.5%)
Cohort,
retrospective,
12 months
Trenk,
632008,
Germany,
single centre
ND 21 (20.0%) (*2);
10.5%
MACE (CV
death, MI), 6
(5.7%)
300 or 600 mg,
NR; 100%
aspirin
Smoking 44.8%,
hypertension 50.5%,
dyslipidaemia
34.3%, diabetes
17.1%
n=105, 70.5%
men, age 60.0
years, BMI 27.6
ACS (STEMI
81.9%, PCI
100%, DES NR)
Cohort,
prospective,
12 months
Malek,
642008,
Poland, single
centre
ND 395 (27.1%)
(*2,*3,*4,*5,*8);
14.8%
MACE (CV
death, MI,
stroke) 129
(8.8%); ST
(definite and
probable) 17
(1.2%)
300 mg, ≤15
months (median
14.5 months)†;
99% aspirin†
Smoking 38.1%,
hypertension 65.8%,
dyslipidaemia
49.1%, diabetes
21.8%
n=1459, 70.5%
men, age 60.1
(11.1) years,
median BMI 28†
ACS (STEMI
29.2%, PCI 95%,
DES 47%†)
Substudy of
RCT,
retrospective,
15 months
Mega,
342009;
US, Europe,
Oceania,
Africa;
multicentre
774 (35.8%),
MAF: 20.2%
635 (28.8%)
(*2,*3,*4,*5), MAF:
15.7%
MACE (death,
MI, stroke) 294
(13.3%)
<300-900(mean
300) mg, NR;
98.4% aspirin
Smoking 54.6%†,
hypertension 58.0%,
dyslipidaemia
49.3%, diabetes
31.6%
n=2208, 70.6%
men, age 66.2
years, BMI 27.2
Acute MI (STEMI
53.2%, PCI
69.5%, DES NR)
Cohort,
retrospective,
12 months
Simon,
652009,
France,
multicentre
ND 73 (28.2%)
(*2,*3,*4,*5,*6);
15.8%
MACE (CV
death, MI), 19
(7.3%);ST
(definite), 12
(5.4%)
NR, median
13.0 (IQR
3.4-36.0)
months; 97.3%
aspirin
Smoking 56.0%,
hypertension 20.1%,
dyslipidaemia
54.0%, diabetes
10.4%
n=259, 92.3%
men, age 40.1
(5.1), BMI 25.7
(3.8)
MI (STEMI
78.8%, PCI
73.0%, DES
32.0%)
Cohort,
retrospective,
mean: 34.6
(maximum 96)
months
Collet,
662009,
France,
multicentre
ND 680 (27.4%) (*2);
14.6%
MACE (death,
MI) 173 (7.0%);
ST (definite) 17
(0.7%)
600 mg, ≥1
month; >95%
aspirin
Smoking 16.2%,
hypertension 62.9%,
dyslipidaemia
48.5%, diabetes
35.5%
n=2485, 78.3%
men, age 66.5
(10.2) years, BMI
27.2 (3.9)
Stable and
unstable angina
and NSTEMI
(ACS 34%, PCI
100%, DES
25.1%)
Substudy of
RCTs,
retrospective,
1 month
Sibbing,
67
2009,
Germany,
single centre
ND 247 (32.0%) (*2);
17.7%
MACE (CV
death), 18
(2.3%); ST
(definite) 11
(1.4%)
600 mg, ≥6
months; 100%
aspirin
Smoking 34.4%,
hypertension 65.4%,
dyslipidaemia
59.7%, diabetes
22.2%
n=772, 74.6%
men, age 69 (11)
years‡, BMI NR
Stable angina
and ACS (ACS
65.7% PCI
100%, DES
100%)
Cohort,
retrospective,
6 months
Giusti,
68 2009,
Italy, single
centre
622 (40.8%),
MAF: 22.9%
ND MACE (MI) 50
(3.3%); ST
(definite and
probable) 14
(0.9%)
600 mg, NR;
99.1% aspirin§
Smoking13.6%,91.
hypertension 3%,
dyslipidaemia
70.1%, diabetes
28.2%
n=1524, 77.4%
men, age 67.4
years, BMI 27.5
Stable angina
and ACS (ACS
33.1%§, PCI
100%, DES
98.0%§)
Cohort,
retrospective,
1 month
Sibbing,
69
2010,
Germany,
single centre
363 (39.1%),
MAF: 22.5%
248 (26.7%) (*2);
14.4%
MACE (death,
MI, stroke) 82
(8.8%); ST
(definite and
probable) 10
(1.1%)
600 mg, ≥6
months; 97.4%
aspirin
Smoking 36.5%,
hypertension 74.5%,
dyslipidaemia
51.9%, diabetes
24.1%
n=928, 74.8%
men, age 64.8
years, BMI 27.0
Acute MI (STEMI
NR, PCI 97.5%,
DES >90%)
Cohort,
prospective,
12 months
Tiroch,
70 2010,
Germany,
single centre
NR (no
association
with efficacy
outcome
reported)
1388 (28.3%)
(*2,*3,*4,*5,*6,*7,*8);
15.4%
MACE (CV
death, MI,
stroke) 481
(9.8%); ST
(definite) 56
(1.7%)
300-600 mg,
median 9.2 (IQR
6-12) months;
96.1% aspirin
Smoking 35.5%,
hypertension
65.1%¶,
dyslipidaemia
46.7%¶, diabetes
23.1%
n=4904, 69.4%
men, age 62.5
(11.0) years,
median BMI 27¶
ACS (STEMI
38%¶, PCI
60.8%¶, DES
18.9%¶)
Substudy of
RCT,
retrospective,
12 months
Wallentin,
18
2010; America,
Europe,
Oceania, Asia;
multicentre
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d4588 doi: 10.1136/bmj.d4588 Page 12 of 18
RESEARCHTable 1 (continued)
No (%) of participants with ≥1
allele; MAF
No (%) of
events
Clopidogrel
loading dose,
treatment
duration;
aspirin
comedication
Cardiovascular
risk factors
Demographics
(mean (SD)
unless stated
otherwise)
Diagnosis at
entry Design Study
Gain of
function
CYP2C19*17
Loss of function
CYP2C19 (at least
*2)
999 (39.1%);
NA
650 (25.7%) (*2,*3);
14.1%
MACE (CV
death, MI,
300 mg, mean 9
(range 3-12)
Smoking 23.1%,
hypertension
n=2530, 58.8%
men, age 63.8
Unstable angina
and NSTEMI
Substudy of
RCT (CURE),
Pare,
192010;
America,
stroke) 230
(9.1%)
months; >94%
aspirin
59.9%**,
dyslipidaemia NR,
diabetes 20.7%
(11.0) years, BMI
27.7 (4.2)
(STEMI 0%, PCI
15.5%, DES 0%)
retrospective,
12 months
Europe,
Oceania;
multicentre
ND 193 (32.4%) (*2);
18.3%
ST (definite)
176 (29.5%)††
NR, ≥ 12
months; 100%
aspirin
Smoking 15.1%,
hypertension 48.7%,
dyslipidaemia
51.0%, diabetes
16.8%
n=596, 79.0%
men, age 62.7
(10.3) years, BMI
27.3
Stable angina
and ACS (ACS
40.1%, PCI
100%, DES
42.6%)
Case-control,
retrospective,
12 months
Harmsze,
71
2010,
Netherlands,
multicentre
ND 42 (42.0%) (*2); NA MACE (death,
MI) 4 (4.0%)
300 mg,
≥follow-up
period; 100%
aspirin
Smoking 41.0%,
hypertension 81.0%,
dyslipidaemia
69.0%, diabetes
42.0%
n=100, 85.0%
men, age 69.6
years, BMI 23.7
Stable angina
and ACS (ACS
9.0%, PCI 100%,
DES 100%)
Cohort,
prospective,
mean 8.1
(range 0.23 to
18.2) months
Sawada,
72
2010, Japan,
single centre
ND 2394 (31.0%)‡‡
(*2,*3,*4,*5); 16.9%
ST (definite) 41
(0.5%)
300-600 mg,
median 12
(range 6-12)
months; 91.2%
aspirin
Smoking 34.8%,
hypertension 55.4%,
dyslipidaemia
51.8%, diabetes
25.9%
n=7719, 79.5%
men, age 61.2
(8.5) years, BMI
27.0 (3.2)
Stable angina
and ACS (ACS
50.9%, PCI
100%, DES
40.2%)
Case-cohort,
prospective,
18 months
Bouman,
20
2010a;
Germany,
Netherlands;
multicentre
747 (37.7%);
20.9%
678 (34.2%)
(*2,*3,*4,*5,*6,*7,*8);
18.8%
MACE (CV
death, MI,
stroke) 216
(10.9%); ST
(definite) 44
(2.2%)
600 mg, ≥12
months; 100%
aspirin
Smoking 35.8%,
hypertension 62.7%,
dyslipidaemia
55.4%, diabetes
24.3%
n=1982, 71.3%
men, age 62.1
(10.2) years, BMI
27.1 (4.2)
ACS (STEMI
38.6% PCI
100%, DES
30.9%)
Cohort,
prospective,
12 months
Bouman,
20
2010b;
Germany,
Netherlands;
multicentre
ACS=acute coronary syndrome; BMI=body mass index; CV death=cardiovascular death; DES=drug eluting stent; IQR=interquartile range; MACE=major adverse
cardiovascular event; MAF=minor allele frequency; MI=myocardial infarction; ND=not determined; NR=not reported; NA=not available from reported data;
NSTEMI=non-ST segment elevation myocardial infarction; PCI=percutaneous coronary intervention; RCT=randomised controlled trial; SD=standard deviation;
ST=stent thrombosis; STEMI=ST segment elevation myocardial infarction; BMS=bare metal stent.
†In 6795 patients assigned to clopidogrel treatment.
79
‡In 804 patients.
80
§In 1608 patients.
81
¶In 9291 patients assigned to clopidogrel treatment.
82
**In 6259 patients assigned to clopidogrel treatment.
83
††Because of case-control design percentage does not reflect proportion of events in population.
‡‡Genotype distribution extrapolated to total cohort.
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RESEARCHTable 2| Epidemiological and genetic quality assessment of included studies of effect of variants of the cytochrome P450 (CYP) 2C19
genotype on clinical efficacy of clopidogrel
Hardy-Weinberg
equilibrium§: Genotyping:
errors;
Blinding:
outcome
Standardised
definition and
Evidence of
population
Demographic and clinical
homogeneity between
groups
Funding
Newcastle-Ottawa
score (0-8); loss to
follow-up Study
loss of function
alleles¶;
CYP2C19*17;
assumed
genetic model
method
(validation
markers);
call rate‡
assessment
to
genotypes†;
genotyping
to outcome
status
assessment
of outcomes
stratification,
ethnicity
With/without
exposure to
genotype of
interest
With/without
outcome
Yes (P=0.30); ND;
dominant
No; validated
TaqMan PCR;
99.3%
Yes; unclear Yes Unclear,
ethnicity NR
Yes Unclear Institutional
grant
8; 0.9% Trenk
63
(2008)
Yes (P=1); ND;
dominant
No; restriction
fragment
length PCR;
100%
Unclear;
unclear
Unclear Unclear,
ethnicity NR
Yes Unclear Institutional
grant
6; 0% Malek
64
(2008)
Yes (P=0.48); ND;
dominant
No; Affymetrix
DMET chip;
98.8%
Yes; unclear Yes No, 97.6%
white (self
reported)
Yes Unclear Industry 8; 0.7%** Mega
34
(2009)
Yes (P=0.57); yes
(P=0.12);
codominant
No; SNPlex
oligoligation or
TaqMan PCR;
>98.0%
Yes; unclear Yes Unclear,
ethnicity NR
Unclear No (patients
with outcome
event were
older, had
higher
prevalence of
Industry,
state
7; 0.8% Simon
65
(2009)
CV risk factors
and less often
underwent PCI)
Yes (P=0.24); ND;
dominant
No; TaqMan
PCR; 100%
Unclear; yes Yes No, 78.0%
white (method
of assessment
NR)
Yes No (hazard
ratios of
outcomes
changed after
adjustment for
patients’
characteristics)
Institutional
grant
6; 0% Collet
66
(2009)
(Yes (P=0.38); ND;
dominant and
codominant
models
No; TaqMan
PCR (quality
checks);100%
Yes; unclear Yes Unclear,
ethnicity NR
Yes Unclear Institutional
grant
8; 6.6% Sibbing
67
(2009)
Yes (P=0.62); ND;
dominant and
codominant
models
No; restriction
fragment
length PCR;
100%
Yes; unclear Yes Unclear,
ethnicity NR
Unclear Unclear, NR Institutional
grant
7; 4% Giusti
68
(2009)
ND; yes (P=0.61);
dominant and
co-dominant
models
No, TaqMan
PCR (quality
checks);100%
Yes; yes Yes Unclear,
ethnicity NR
Yes Unclear Industry
and
institutional
grant
8; 5.2% Sibbing
69
(2010)
Yes (P=0.69); yes
(P=0.19); dominant
No; TaqMan
PCR (quality
checks);100%
Unclear;
unclear
Yes Unclear,
ethnicity NR
Yes Yes Institutional
grant
7; 0% Tiroch
70
(2010)
Yes (P=0.35);
unclear; dominant
No; TaqMan
PCR; ≥98.8%
Yes; unclear Yes No, 98.3%
white (self
reported)
Unclear Unclear Industry 7; 4.7% Wallentin
18
(2010)
Yes (P=0.07); yes
(P>0.05)‡‡;
dominant and
codominant
models
No; TaqMan
PCR; >98%
Yes; unclear Yes No, 86.2%
white, 13.8%
Hispanics (self
reported)
Unclear Unclear Industry 7; 0.1%†† Pare
19
(2010)
Yes (P=0.16); ND;
dominant
No; TaqMan
PCR; 100%
Yes; unclear Yes Unclear,
ethnicity NR
Unclear No (patients
with outcome
event had more
ACS, were
more often
smokers, and
No funding 7; 5.4% Harmsze
71
(2010)
fewer received
DES)
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RESEARCHTable 2 (continued)
Hardy-Weinberg
equilibrium§:
loss of function
alleles¶;
CYP2C19*17;
assumed
genetic model
Genotyping:
errors;
method
(validation
markers);
call rate‡
Blinding:
outcome
assessment
to
genotypes†;
genotyping
to outcome
status
Standardised
definition and
assessment
of outcomes
Evidence of
population
stratification,
ethnicity
Demographic and clinical
homogeneity between
groups
Funding
Newcastle-Ottawa
score (0-8); loss to
follow-up Study
With/without
exposure to
genotype of
interest
With/without
outcome
Unclear (genotype
frequencies NR);
ND; dominant
No; TaqMan
PCR; 100%
Yes; unclear Yes No, 100% East
Asian (method
of assessment
NR)
Yes Unclear No funding 5; 72.8% Sawada
72
(2010)
Yes (P=0.90)§§;
ND; codominant
No; direct
sequencing
(validation
rules), 100%
Yes; yes Yes No, 100% white
(self reported,
genomic
control)
Yes Yes No funding 7; 1.3% Bouman
20
(2010a)
Yes (P=0.88); yes
(P=0.64);
codominant
No; direct
sequencing
(validation
rules), 99.5%
Yes; yes Yes No, 100% white
(self reported)
Yes Yes No funding 8; 8.4% Bouman
20
(2010b)
ACS=acute coronary syndrome; CV=cardiovascular; PCI=percutaneous coronary intervention; DES=drug eluting stent; NR=not reported; ND=not determined;
PCR= polymerase chain reaction.
†Outcome assessors classified as blinded to genotype if explicitly reported or genotyping conducted in subsequent study.
‡Fraction of complete and non-missing genotypes of number of total genotypes
§With Fisher’s exact test P value.
¶For testing deviation from Hardy-Weinberg equilibrium observed genotype frequencies of all loss of function alleles of CYP2C19 combined.
**From Mega et al.
14
††In 6259 patients assigned to clopidogrel treatment.
83
‡‡P value stated by authors (genotype distribution not presented).
§§P value derived from genotype distribution extrapolated to total cohort of 7719 patients (P=0.53, exact P value for genotype distribution of random subcohort).
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RESEARCHFigures
Fig 1 Selection of studies of association of CYP2C19 variant genes with cardiovascular events in patients treated with
clopidogrel
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RESEARCHFig 2 Association between loss of function polymorphisms of CYP2C19 and major adverse cardiovascular events (MACE)
or stent thrombosis in patients with coronary artery disease taking clopidogrel treatment. Odds ratios shown for individual
studies for dominant model genotype contrasts (carriers of one or two loss of function alleles v non-carriers). Cumulative
odds ratios shown for each additional information step obtained by stepwise inclusion of every new study into pooled
estimate
Fig 3 Association between gain of function CYP2C19*17 polymorphisms with major adverse cardiovascular events (MACE)
or stent thrombosis in patients with coronary artery disease receiving clopidogrel treatment. Odds ratios shown for individual
studies for dominant model genotype contrasts (carriers of one or two gain of function alleles v non-carriers). Cumulative
odds ratios shown for each additional information step obtained by stepwise inclusion of every new study into pooled
estimate
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RESEARCHFig 4 Funnel plots for association studies of loss of function genotypes of CYP2C19 with major adverse cardiovascular
events (MACE) or stent thrombosis and for association studies of the gain of function variant CYP2C19*17 with MACE.
Solid vertical line represents summary effect estimate, derived by using fixed effects meta-analysis for displaying centre of
plot in absence of bias.
78 Red lines represent 95% confidence limits for expected distribution of studies in absence of
heterogeneity between studies or of selection biases
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